

Cite this as: Shuang LIU, Hongsheng CHEN, Zaiwei SONG, Qi GUO, Xianglin ZHANG, Bingyi SHI, Suodi ZHAI, Lingli ZHANG, Liyan MIAO, Liyan CUI, Xiao CHEN, Yalin DONG, Weihong GE, Xiaofei HOU, Ling JIANG, Long LIU, Lihong LIU, Maobai LIU, Tao LIN, Xiaoyang LU, Lulin MA, Changxi WANG, Jianyong WU, Wei WANG, Zhuo WANG, Ting XU, Wujun XUE, Bikui ZHANG, Guanren ZHAO, Jun ZHANG, Limei ZHAO, Qingchun ZHAO, Xiaojian ZHANG, Yi ZHANG, Yu ZHANG, Rongsheng ZHAO, 2025. A practice guideline for therapeutic drug monitoring of mycophenolic acid for solid organ transplants. *Journal of Zhejiang University-SCIENCE B*, 26(9):897-914. <https://doi.org/10.1631/jzus.B2400069>

A practice guideline for therapeutic drug monitoring of mycophenolic acid for solid organ transplants

Key words: Guideline, Mycophenolic acid (MPA), Therapeutic drug monitoring (TDM), Grading of Recommendations Assessment, Development, and Evaluation (GRADE), Solid organ transplant

Research summary

The evidence-based guideline offers a comprehensive recommendation for solid organ transplant recipients undergoing mycophenolic acid therapy, promoting standardization of mycophenolic acid therapeutic drug monitoring and enhancing treatment efficacy and safety.




Figure 2 The framework of guideline for the TDM of MPA

Innovation points

- **Evidence-Based MPA TDM Guideline Development**
 - A pioneering approach to tailor MPA therapy for solid organ transplants.
- **Adoption of Renowned Frameworks**
 - Integration of guidelines from the Institute of Medicine and WHO for a robust foundation.
- **Delphi Method for Clinical Inquiry**
 - Utilizing expert consensus to formulate clinical questions and outcome indicators.
- **Multifaceted Evaluation Approach**
 - Systematic reviews, GRADE assessments, expert insights, and patient values converge to inform guideline recommendations.
- **Comprehensive Guideline Structure**
 - A four-part guideline with 16 recommendations covering a wide array of considerations for MPA TDM.

Innovation points

A series of comprehensive figures and tables were generated to summarize the latest knowledge about mycophenolic acid therapeutic drug monitoring.

Figure 1 | The pharmacokinetic and pharmacodynamic pathways of MPA

Figure 2 | The framework of the guideline for the TDM of MPA

Table 1 | Grading system for recommendations based on quality of evidence

Table 2 | The recommended C_0 ranges

Table 3 | The recommended AUC ranges

Table 4 | Recommendations for special populations

Table 5 | Management of co-administered drugs of MPA